Compare MITT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | TNXP |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.5M | 199.7M |
| IPO Year | 2011 | 2008 |
| Metric | MITT | TNXP |
|---|---|---|
| Price | $6.05 | $9.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | 297.4K | ★ 411.2K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 11.96% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $3.48 | $558.11 |
| Revenue Next Year | $5.06 | $38.29 |
| P/E Ratio | $611.00 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $5.93 | $9.40 |
| 52 Week High | $9.27 | $24.64 |
| Indicator | MITT | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 28.71 | 27.93 |
| Support Level | $5.93 | $9.40 |
| Resistance Level | $6.85 | $12.99 |
| Average True Range (ATR) | 0.16 | 0.56 |
| MACD | -0.03 | -0.27 |
| Stochastic Oscillator | 12.03 | 9.00 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.